Ironwood Pharmaceuticals Total Assets 2010-2025 | IRWD

Ironwood Pharmaceuticals total assets from 2010 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.
Ironwood Pharmaceuticals Annual Total Assets
(Millions of US $)
2024 $351
2023 $471
2022 $1,101
2021 $1,127
2020 $559
2019 $403
2018 $332
2017 $606
2016 $710
2015 $619
2014 $329
2013 $279
2012 $230
2011 $209
2010 $301
2009 $162
Ironwood Pharmaceuticals Quarterly Total Assets
(Millions of US $)
2025-03-31 $327
2024-12-31 $351
2024-09-30 $390
2024-06-30 $396
2024-03-31 $439
2023-12-31 $471
2023-09-30 $524
2023-06-30 $603
2023-03-31 $1,155
2022-12-31 $1,101
2022-09-30 $1,040
2022-06-30 $976
2022-03-31 $1,083
2021-12-31 $1,127
2021-09-30 $1,079
2021-06-30 $1,007
2021-03-31 $599
2020-12-31 $559
2020-09-30 $492
2020-06-30 $444
2020-03-31 $404
2019-12-31 $403
2019-09-30 $334
2019-06-30 $316
2019-03-31 $364
2018-12-31 $332
2018-09-30 $417
2018-06-30 $618
2018-03-31 $571
2017-12-31 $606
2017-09-30 $625
2017-06-30 $705
2017-03-31 $701
2016-12-31 $710
2016-09-30 $732
2016-06-30 $700
2016-03-31 $603
2015-12-31 $619
2015-09-30 $613
2015-06-30 $654
2015-03-31 $306
2014-12-31 $329
2014-09-30 $346
2014-06-30 $371
2014-03-31 $419
2013-12-31 $279
2013-09-30 $326
2013-06-30 $384
2013-03-31 $325
2012-12-31 $230
2012-09-30 $247
2012-06-30 $209
2012-03-31 $249
2011-12-31 $209
2011-09-30 $219
2011-06-30 $250
2011-03-31 $272
2010-12-31 $301
2010-09-30 $305
2010-06-30 $322
2010-03-31 $338
2009-12-31 $162
2009-09-30 $150
2009-06-30 $0
2009-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.097B $0.351B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $85.830B 32.20
Zoetis (ZTS) United States $75.075B 28.01
Daiichi Sankyo, - (DSNKY) Japan $50.952B 25.92
Takeda Pharmaceutical (TAK) Japan $47.824B 9.51
Sandoz Group AG (SDZNY) Switzerland $22.282B 0.00
Merck (MKKGY) Germany $17.034B 12.48
United Therapeutics (UTHR) United States $14.382B 12.72
Shionogi (SGIOY) Japan $14.036B 0.00
Summit Therapeutics (SMMT) United States $13.528B 0.00
Neurocrine Biosciences (NBIX) United States $12.175B 41.70
IPSEN (IPSEY) France $9.924B 0.00
Orion OYJ (ORINY) Finland $9.462B 25.59
Corcept Therapeutics (CORT) United States $8.225B 66.86
Stevanato Group S.p.A (STVN) Italy $6.726B 41.13
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.153B 0.00
Madrigal Pharmaceuticals (MDGL) United States $6.112B 0.00
Grifols, S.A (GRFS) Spain $5.714B 0.00
Ionis Pharmaceuticals (IONS) United States $5.333B 0.00
Ono Pharmaceutical (OPHLF) Japan $4.875B 14.83
Soleno Therapeutics (SLNO) United States $3.696B 0.00
Catalyst Pharmaceuticals (CPRX) United States $3.045B 10.67
Crinetics Pharmaceuticals (CRNX) United States $2.857B 0.00
Hypermarcas (HYPMY) Brazil $2.812B 18.50
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.294B 12.41
BioCryst Pharmaceuticals (BCRX) United States $2.249B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.033B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.804B 0.00
Indivior (INDV) United States $1.773B 7.52
Recursion Pharmaceuticals (RXRX) United States $1.699B 0.00
ARS Pharmaceuticals (SPRY) United States $1.417B 0.00
Evotec AG (EVO) Germany $1.410B 0.00
Dyne Therapeutics (DYN) United States $1.359B 0.00
Guardian Pharmacy Services (GRDN) United States $1.340B 0.00
Ocular Therapeutix (OCUL) United States $1.276B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.059B 21.19
Harrow (HROW) United States $1.031B 0.00
Collegium Pharmaceutical (COLL) United States $0.936B 5.05
Avadel Pharmaceuticals (AVDL) Ireland $0.881B 0.00
Ardelyx (ARDX) United States $0.878B 0.00
Enliven Therapeutics (ELVN) United States $0.872B 0.00
Akebia Therapeutics (AKBA) United States $0.796B 0.00
Xeris Biopharma Holdings (XERS) United States $0.773B 0.00
Cronos Group (CRON) Canada $0.763B 0.00
AleAnna (ANNA) United States $0.624B 0.00
KalVista Pharmaceuticals (KALV) United States $0.587B 0.00
Elite Pharmaceuticals (ELTP) United States $0.577B 0.00
Xencor (XNCR) United States $0.569B 0.00
USANA Health Sciences (USNA) United States $0.556B 12.09
Regulus Therapeutics (RGLS) United States $0.549B 0.00
Bioventus (BVS) United States $0.532B 13.50
Relay Therapeutics (RLAY) United States $0.514B 0.00
Zevra Therapeutics (ZVRA) United States $0.468B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.459B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.458B 0.00
Altimmune (ALT) United States $0.440B 0.00
Tourmaline Bio (TRML) United States $0.428B 0.00
Siga Technologies (SIGA) United States $0.427B 8.93
Oruka Therapeutics (ORKA) United States $0.410B 0.00
Verve Therapeutics (VERV) United States $0.397B 0.00
Savara (SVRA) United States $0.394B 0.00
Organogenesis (ORGO) United States $0.348B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.343B 9.28
Tonix Pharmaceuticals Holding (TNXP) United States $0.291B 0.00
Heron Therapeutics (HRTX) United States $0.287B 0.00
Nature's Sunshine Products (NATR) United States $0.284B 26.20
Aquestive Therapeutics (AQST) United States $0.269B 0.00
MediWound (MDWD) Israel $0.237B 0.00
ProKidney (PROK) United States $0.212B 0.00
Nanobiotix S.A (NBTX) France $0.193B 0.00
Journey Medical (DERM) United States $0.188B 0.00
Esperion Therapeutics (ESPR) United States $0.168B 0.00
4D Molecular Therapeutics (FDMT) United States $0.168B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.164B 0.00
Profound Medical (PROF) Canada $0.158B 0.00
Aclaris Therapeutics (ACRS) United States $0.158B 0.00
OmniAb (OABI) United States $0.155B 0.00
Inhibikase Therapeutics (IKT) United States $0.149B 0.00
Avita Medical (RCEL) United States $0.149B 0.00
Wellgistics Health (WGRX) United States $0.144B 0.00
Larimar Therapeutics (LRMR) United States $0.144B 0.00
Liminatus Pharma (LIMN) $0.141B 0.00
Nektar Therapeutics (NKTR) United States $0.135B 0.00
Lyell Immunopharma (LYEL) United States $0.129B 0.00
Aldeyra Therapeutics (ALDX) United States $0.129B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.127B 0.00
Achieve Life Sciences (ACHV) Canada $0.124B 0.00
Innate Pharma SA (IPHYF) France $0.122B 0.00
Protara Therapeutics (TARA) United States $0.117B 0.00
Korro Bio (KRRO) United States $0.107B 0.00
Cardiol Therapeutics (CRDL) Canada $0.103B 0.00
VAXART, INC (VXRT) United States $0.099B 0.00
OptiNose (OPTN) United States $0.097B 0.00
Cassava Sciences (SAVA) United States $0.097B 0.00
Fractyl Health (GUTS) United States $0.093B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.091B 0.00
Lexeo Therapeutics (LXEO) United States $0.090B 0.00
Inotiv (NOTV) United States $0.089B 0.00
Arch Biopartners (ACHFF) Canada $0.085B 0.00
Galectin Therapeutics (GALT) United States $0.083B 0.00
Champions Oncology (CSBR) United States $0.081B 13.34
Pyxis Oncology (PYXS) United States $0.075B 0.00
Vivani Medical (VANI) United States $0.075B 0.00
ESSA Pharma (EPIX) Canada $0.075B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.074B 55.11
Surrozen (SRZN) United States $0.073B 0.00
Nutriband (NTRB) United States $0.073B 0.00
Unicycive Therapeutics (UNCY) United States $0.071B 0.00
Dominari Holdings (DOMH) United States $0.065B 0.00
Assertio Holdings (ASRT) United States $0.064B 0.00
Metagenomi (MGX) United States $0.064B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
Telomir Pharmaceuticals (TELO) United States $0.058B 0.00
Gain Therapeutics (GANX) United States $0.053B 0.00
Context Therapeutics (CNTX) United States $0.052B 0.00
Prelude Therapeutics (PRLD) United States $0.050B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.046B 0.00
Century Therapeutics (IPSC) United States $0.046B 0.00
NRx Pharmaceuticals (NRXP) United States $0.046B 0.00
PMV Pharmaceuticals (PMVP) United States $0.046B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.045B 0.00
Mural Oncology (MURA) Ireland $0.045B 0.00
Avalo Therapeutics (AVTX) United States $0.043B 0.00
Iterum Therapeutics (ITRM) Ireland $0.040B 0.00
ElectroCore (ECOR) United States $0.037B 0.00
Karyopharm Therapeutics (KPTI) United States $0.036B 0.00
Rafael Holdings (RFL) United States $0.036B 0.00
SCYNEXIS (SCYX) United States $0.034B 0.00
Acrivon Therapeutics (ACRV) United States $0.033B 0.00
FibroGen (FGEN) United States $0.029B 0.00
PolyPid (PYPD) Israel $0.029B 0.00
Jupiter Neurosciences (JUNS) United States $0.026B 0.00
Relmada Therapeutics (RLMD) United States $0.025B 0.00
CASI Pharmaceuticals (CASI) China $0.023B 0.00
Enlivex Therapeutics (ENLV) Israel $0.022B 0.00
China SXT Pharmaceuticals (SXTC) China $0.022B 0.00
Tempest Therapeutics (TPST) United States $0.022B 0.00
Natural Alternatives (NAII) United States $0.021B 0.00
BioVie (BIVI) United States $0.019B 0.00
Mannatech (MTEX) United States $0.019B 0.00
Lipocine (LPCN) United States $0.018B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.018B 0.00
BioLineRx (BLRX) Israel $0.017B 0.00
TherapeuticsMD (TXMD) United States $0.017B 0.00
DURECT (DRRX) United States $0.016B 0.00
ProPhase Labs (PRPH) United States $0.015B 0.00
MEI Pharma (MEIP) United States $0.015B 0.00
VYNE Therapeutics (VYNE) United States $0.014B 0.00
Vivos Therapeutics (VVOS) United States $0.014B 0.00
Ainos (AIMD) United States $0.014B 0.00
Ernexa Therapeutics (ERNA) United States $0.014B 0.00
GlycoMimetics (GLYC) United States $0.014B 0.00
Cosmos Health (COSM) United States $0.013B 0.00
Scienture Holdings (SCNX) United States $0.011B 0.00
Mangoceuticals (MGRX) United States $0.011B 0.00
Minerva Neurosciences (NERV) United States $0.011B 1.88
Talphera (TLPH) United States $0.010B 0.00
Phio Pharmaceuticals (PHIO) United States $0.010B 0.00
SHINECO (SISI) China $0.009B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Carisma Therapeutics (CARM) United States $0.008B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.008B 0.00
Traws Pharma (TRAW) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Citius Pharmaceuticals (CTXR) United States $0.007B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.007B 0.00
Lyra Therapeutics (LYRA) United States $0.007B 0.00
Incannex Healthcare (IXHL) Australia $0.006B 0.00
Klotho Neurosciences (KLTO) United States $0.006B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Indaptus Therapeutics (INDP) United States $0.005B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
Plus Therapeutics (PSTV) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Jaguar Animal Health (JAGX) United States $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Redhill Biopharma (RDHL) Israel $0.004B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
PainReform (PRFX) Israel $0.004B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
CERo Therapeutics Holdings (CERO) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Aditxt (ADTX) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Conduit Pharmaceuticals (CDT) United States $0.003B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00